Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers was compared in a randomized prospective trial with intravenous cephapirin therapy. Dosage regimens were ceforanide, 1 g every 12 h, and cephapirin, 2 g every 4 h. Mean minimal inhibitory and bactericidal concentrations of ceforanide for S. aureus treated with ceforanide were 0.78 and 1.56 ,ug/ml compared to cephapirin for patient isolates of 0.08 and 0.14 p,g/ml, respectively. Serum killing levels with ceforanide were 1:5.7 and 1:1.5 at peak and trough levels, compared to 1:134 (peak) and 1:4.2 (trough) with cephapirin. Despite this apparent in vitro advantage of cephapirin, patients treated with ceforanide did as well as those with cephapirin. Of 16 ceforanide-treated patients, all responded initially to therapy, and 15 were cured with 28 days of therapy. One patient relapsed at the end of therapy. Of 16 cephapirin-treated patients, 1 was a clinical and microbiological failure, and 3 others relapsed at the end of therapy. In addition, one ceforanide-treated patient and two cephapirin-treated patients developed central nervous system abscesses. These were cured with drainage and continuation of antibiotic therapy. Ceforanide was well tolerated by the intramuscular route. Cost analysis suggests that therapy with intramuscular ceforanide would result in an approximate 70% decrease in drug therapy cost when compared to intravenous cephapirin. Ceforanide appears to be a safe, efficacious, convenient, and relatively inexpensive drug for treating staphylococcal endocarditis in parenteral drug abusers.
Bacterial endocarditis is a common complication of intravenous drug abuse. Endocarditis in intravenous drug abusers is most frequently caused by Staphylococcus aureus and usually involves the right side of the heart (1, 2, 7, 9, 11, 15, 16) . Mortality from this disease, when appropriately treated, has been low in most reported series from the last decade (1, 7, 9, 15, 16) . Recently, single-drug intravenous 3-lactam antibiotic therapy has been shown to be as efficacious in effecting a cure as combination therapy, including an aminoglycoside antibiotic (1, 7) . Such intravenous therapy requires continuous intravenous access for 4 weeks in patients with already traumatized veins. This has presented a problem in completing therapy and has frequently led to the necessity of placement of central catheters or surgically placed peripheral catheters. Prolonged intravenous therapy thus has an inherent risk of nosocomial, catheter-related bacteremia. In addition, a small proportion of patients refuse such invasive therapeutic access and have left the hospital prematurely, against medical advice.
Ceforanide (BL-S786R) is an investigational cephalosporin antibiotic that is usually well tolerated intramuscularly in doses up to 2 g (12) . The pharmacokinetics of the agent demonstrate a mean serum half-life of 2.2 to 3.0 h (4, 5, 12 (10) .
Because of the potential therapeutic and economic advantages of a twice-daily intramuscular regimen for treating staphylococcal endocarditis in drug abusers, we undertook a study to compare the efficacy of ceforanide therapy with that of a standard intravenous regimen; in this study 2 g of cephapirin was administered intravenously every 4 h. We felt justified in treating with a cephalosporin alone pending culture results, since, at our institution over the previous 4 Endocarditis was diagnosed by criteria that we have previously employed (1, 15 Patients were evaluated daily by a member of the Infectious Diseases Division for such features as fever, congestive heart failure, or evidence of metastatic infectious foci. Complete blood count, sedimentation rate, urinalysis, and hepatic and renal function tests were obtained on a weekly basis unless the patient's clinical status dictated more frequent testing. Roentgenographic examinations and echocardiograms were obtained when appropriate.
Repeat blood cultures were obtained on days 3 and 7 and then weekly for the course of therapy. MIC and MBC of the treatment drug (cephapirin or ceforanide) for infecting organisms were determined by broth dilution studies by the method of Barry and Sabath (3) . Serum bactericidal titers were determined on serum obtained at times corresponding to peak (30 min after either drug) and trough (11.5 h after ceforanide and 3.5 h after cephapirin) serum antibiotic concentrations on day 5. Serum antibiotic concentrations were determined on these samples by high-pressure liquid chromatography, courtesy of Bristol Laboratories.
All patients were seen as outpatients 2 to 6 weeks (mean, 3.5 weeks) after completion of therapy, and physical examinations and repeat blood cultures were performed. Cure was defined as being clinically well and having negative blood cultures at this follow-up visit.
RESULTS
Therapy was begun for 54 suspected episodes of endocarditis. Fourteen patients subsequently did not fulfill the criteria for continuation in the study. Eight patients had sterile blood cultures, three had alpha-streptococcal endocarditis, and one each had group A streptococcal bacteremia, staphylococcal pneumonia with negative blood culture, and bacteremic Escherichia coli pyelonephritis. No patient was excluded from entrance to the study because of clinical severity of disease or the bias of his primary physician toward one form of therapy.
We thus began treatment of 40 patients with S. aureus endocarditis. Of these, eight were eventually not evaluable. Four were withdrawn early in the course of therapy by their primary physician to change to a standard oxacillin regimen. Three of these four were on the ceforanide regimen early in the course of the study. They did well on continued oxacillin therapy and were cured. Three patients left the hospital against medical advice after less than 2 weeks of therapy, and one ceforanide patient was switched to oxacillin because of a protocol exclusion of pregnancy. The 32 patients treated for 4 weeks form the basis of this report.
Demographic and clinical characteristics of the patients are shown in Table 1 . All patients admitted using intravenous drugs, and most had injected a drug intravenously within 1 week of hospitalization. The clinical features of the two groups were comparable. Cerebrospinal fluid pleocytosis was evident in 7 of 12 lumbar punctures, 3 in ceforanide patients and 4 in patients treated with cephapirin. Three patients had central nervous system abscesses which became apparent several weeks into the course of therapy. One ceforanide patient developed a spinal epidural abscess, and two cephapirin patients developed brain abscesses. These three patients were subsequently cured with drainage of their abscesses and continued protocol antibiotic. Septic arthritis, culture positive for S. aureus, occurred in two patients in each group. Most patients in each group were febrile for less than 10 days before admission. Mean peak temperatures during the initial 24 h of hospitalization was similar in both groups (103.6°F for ceforanide and 103.8°F for cephapirin). Initial laboratory data including hematocrit, leukocyte count, serum glutamic-oxalacetic transaminase, (0) Results of MIC and MBC testing for the infecting organisms are shown in Fig. 1 . Mean MIC and MBC of ceforanide were 0.78 0.42 and 1.56 1.23 ,ug/ml, respectively. Mean MIC and MBC of cephapirin were 0.08 0.10 and 0.14 0.17 ,ug/ml, respectively. Peak and trough serum bactericidal levels are shown in Fig. 2 
